Pfizer Says Wyeth Acquisition, Economic Factors Drove Decision to Scuttle Mission Bay Deal | GenomeWeb

This is a second revised version of a story originally published July 8.

By Alex Philippidis

Pfizer's decision to scuttle its plan to lease 105,000 square feet at the Mission Bay campus in San Francisco — less than a year after agreeing to the deal — is a setback for Mission Bay and the Bay Area's lab-space market, which has slumped with the economy over the past year, but not a crippling blow to either, two real estate professionals agreed this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.